Sara A Hurvitz Selected Research

Docetaxel (Taxotere)

12/2021	Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
1/2019	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
1/2018	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
5/2014	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
1/2014	Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.
3/2013	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
8/2010	A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sara A Hurvitz Research Topics

Disease

84	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2008
37	Neoplasms (Cancer) 01/2022 - 09/2005
12	Disease Progression 01/2022 - 06/2005
10	Triple Negative Breast Neoplasms 09/2022 - 01/2018
9	Neoplasm Metastasis (Metastasis) 09/2022 - 04/2012
8	Fatigue 07/2021 - 10/2009
6	Diarrhea 01/2021 - 10/2009
6	Neutropenia 01/2021 - 10/2009
5	Brain Neoplasms (Brain Tumor) 06/2022 - 03/2014
4	Cardiotoxicity 01/2022 - 01/2014
4	Anemia 01/2021 - 01/2018
4	B-Cell Lymphoma (Lymphoma, B Cell) 09/2012 - 09/2005
4	Lymphoma (Lymphomas) 09/2012 - 06/2005
3	Pneumonia (Pneumonitis) 01/2022 - 10/2013
3	Nausea 02/2020 - 01/2020
3	Alopecia (Baldness) 02/2020 - 07/2015
3	Stomatitis 01/2020 - 10/2013
3	Pathologic Complete Response 01/2020 - 09/2018
3	Vomiting 01/2020 - 10/2013
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2009 - 06/2005
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2020
2	Body Weight (Weight, Body) 06/2021 - 01/2020
2	Febrile Neutropenia 01/2021 - 01/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2020 - 03/2014
2	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 10/2009
2	Thrombocytopenia (Thrombopenia) 01/2014 - 10/2009
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Constipation 07/2021
1	Overweight 06/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021

Drug/Important Bio-Agent (IBA)

28	Trastuzumab (Herceptin)FDA Link 01/2022 - 12/2010
25	Hormones (Hormone)IBA 09/2022 - 11/2008
17	human ERBB2 proteinIBA 01/2022 - 12/2010
14	Ado-Trastuzumab EmtansineIBA 01/2022 - 09/2012
13	Capecitabine (Xeloda)FDA Link 11/2021 - 03/2013
13	Lapatinib (GW572016)FDA Link 11/2021 - 04/2012
10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2013
8	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 09/2012
7	Estrogen ReceptorsIBA 01/2022 - 11/2008
7	Docetaxel (Taxotere)FDA Link 12/2021 - 08/2010
7	Proteins (Proteins, Gene)FDA Link 11/2021 - 09/2005
7	Everolimus FDA Link 01/2021 - 12/2010
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2013
6	pertuzumabIBA 12/2021 - 12/2014
6	Paclitaxel (Taxol)FDA LinkGeneric 09/2018 - 08/2010
5	sacituzumab govitecanIBA 09/2022 - 01/2021
5	Cyclin-Dependent Kinase 4IBA 01/2022 - 01/2021
5	talazoparibIBA 01/2022 - 01/2018
4	taxaneIBA 01/2022 - 10/2013
4	AnthracyclinesIBA 01/2022 - 01/2016
4	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2016
4	Gemcitabine FDA Link 01/2021 - 01/2016
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
3	Aromatase InhibitorsIBA 01/2022 - 11/2008
3	palbociclibIBA 01/2022 - 01/2021
3	Letrozole (Femara)FDA LinkGeneric 01/2022 - 01/2018
3	Carboplatin (JM8)FDA LinkGeneric 12/2021 - 01/2018
3	neratinibIBA 11/2021 - 01/2020
3	eribulin FDA Link 01/2021 - 01/2018
3	ribociclibIBA 01/2021 - 01/2018
3	Transaminases (Aminotransferases)IBA 01/2020 - 01/2014
3	Monoclonal AntibodiesIBA 12/2019 - 10/2009
3	Bevacizumab (Avastin)FDA Link 06/2015 - 08/2010
3	TOR Serine-Threonine KinasesIBA 03/2014 - 12/2010
3	VaccinesIBA 09/2008 - 06/2005
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2018
2	trastuzumab deruxtecanIBA 01/2022 - 01/2020
2	exemestane (Aromasin)FDA Link 01/2021 - 02/2015
2	Fulvestrant (Faslodex)FDA Link 01/2021 - 02/2015
2	Epidermal Growth Factor (EGF)IBA 06/2020 - 04/2012
2	Poly Adenosine Diphosphate RiboseIBA 02/2020 - 01/2018
2	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2020 - 09/2008
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 05/2013
2	Biological ProductsIBA 01/2020 - 07/2015
2	PlatinumIBA 01/2019 - 01/2018
2	Cytotoxins (Cytolysins)IBA 01/2018 - 03/2013
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2018 - 03/2014
2	Angiogenesis InhibitorsIBA 01/2018 - 08/2010
2	Progesterone Receptors (Progesterone Receptor)IBA 09/2015 - 09/2009
2	benthiocarb (Bolero)IBA 07/2015 - 07/2014
2	Tamoxifen FDA LinkGeneric 02/2015 - 11/2008
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2014 - 03/2014
2	Rituximab (Mabthera)FDA Link 09/2012 - 06/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 09/2008 - 09/2005
1	Codon (Codons)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021

Therapy/Procedure

53	Therapeutics 06/2022 - 11/2008
22	Drug Therapy (Chemotherapy) 01/2022 - 09/2009
5	Aftercare (After-Treatment) 01/2022 - 01/2018
4	Neoadjuvant Therapy 01/2021 - 01/2017
4	Radiotherapy 01/2021 - 10/2015
3	Adjuvant Chemotherapy 06/2022 - 01/2017
3	Immunotherapy 01/2018 - 06/2005
3	Mastectomy (Mammectomy) 01/2018 - 10/2015
1	Palliative Care (Palliative Therapy) 01/2022